TCRX TScan Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1783328 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-38.4%
TTM net income YoY19.3%
TTM EPS YoY20.5%
Revenue 3-yr CAGR-32.6%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-2,246.8%
Net margin-2,219.2%
FCF margin-2,153.3%
EBITDA margin-2,192.3%
Returns
ROE-126.4%
ROA-57.0%
ROIC (approx.)-3,777.3%
Asset turnover0.03x
Leverage & solvency
Liabilities / assets73.1%
Debt / equity0.87x
Current ratio2.03x
Interest coverage-40.67x
Cash quality & payout
Operating cash flow / net income0.96x
Accruals ratio-2.1%
Payout ratio—
Capex / revenue14.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $586,000 | $1.05M | $982,000 | $2.57M | $2.51M | $3.08M | $2.17M | $665,000 |
| R&D expense | $25.29M | $23.40M | $21.90M | $20.04M | $31.69M | $32.63M | $29.79M | $29.35M |
| SG&A expense | $8.33M | $8.14M | $8.22M | $6.39M | $7.87M | $9.10M | $8.63M | $8.02M |
| Operating income | -$33.03M | -$30.49M | -$29.14M | -$23.86M | -$37.05M | -$38.65M | -$36.25M | -$36.71M |
| Interest expense | $775,000 | $699,000 | $689,000 | $702,000 | $699,000 | $689,000 | $679,000 | $784,000 |
| Net income | -$33.09M | -$30.36M | -$28.67M | -$22.98M | -$35.71M | -$36.95M | -$34.13M | -$35.81M |
| EBITDA | -$32.35M | -$29.79M | -$28.45M | -$23.10M | -$36.28M | -$37.95M | -$35.57M | -$36.01M |
| EPS (basic) | -0.25 | -0.23 | -0.22 | — | -0.28 | -0.28 | -0.26 | — |
| EPS (diluted) | -0.25 | -0.23 | -0.22 | — | -0.28 | -0.28 | -0.26 | — |
| Weighted avg. shares (diluted) | 130.03M | 129.95M | 129.91M | — | 129.84M | 129.73M | 129.68M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $73.04M | $100.16M | $128.06M | $152.41M | $169.51M | $169.39M | $154.11M | $183.72M |
| Short-term investments | — | — | — | — | $14.95M | $48.65M | $97.58M | $111.42M |
| Current assets | $76.78M | $104.40M | $132.77M | $157.21M | $188.16M | $221.13M | $254.84M | $292.72M |
| PP&E, net | $7.11M | $7.74M | $8.12M | $8.71M | $9.30M | $9.52M | $8.35M | $7.24M |
| Total assets | $141.40M | $171.45M | $201.99M | $228.79M | $262.23M | $298.56M | $332.71M | $371.12M |
| Current liabilities | $37.82M | $30.96M | $19.97M | $18.70M | $29.21M | $31.32M | $29.82M | $35.96M |
| Short-term debt | $15.70M | $11.71M | — | — | — | — | — | — |
| Long-term debt | $17.27M | $21.07M | $32.65M | $32.53M | $32.41M | $32.30M | $32.18M | $32.07M |
| Total debt | $32.97M | $32.78M | $32.65M | $32.53M | $32.41M | $32.30M | $32.18M | $32.07M |
| Total liabilities | $103.39M | $102.43M | $105.07M | $105.67M | $118.20M | $121.85M | $122.51M | $130.15M |
| Shareholders' equity | $38.01M | $69.02M | $96.92M | $123.12M | $144.02M | $176.71M | $210.20M | $240.97M |
| Net debt | -$40.07M | -$67.38M | -$95.40M | -$119.87M | -$137.09M | -$137.10M | -$121.93M | -$151.65M |
| Cash flow statement | ||||||||
| Operating cash flow | -$27.08M | -$27.54M | -$24.28M | -$32.00M | -$32.46M | -$33.27M | -$37.59M | -$27.41M |
| Capital expenditure | $41,000 | $493,000 | $70,000 | $171,000 | $1.43M | $1.28M | $1.53M | $888,000 |
| Free cash flow | -$27.12M | -$28.03M | -$24.35M | -$32.17M | -$33.89M | -$34.55M | -$39.12M | -$28.30M |
| Investing cash flow | -$41,000 | -$465,000 | -$70,000 | $14.83M | $32.58M | $48.44M | $13.53M | $27.29M |
| Financing cash flow | $0 | — | — | $73,000 | $0 | $116,000 | -$525,000 | $45.69M |
| Depreciation & amortization | $678,000 | $699,000 | $693,000 | $757,000 | $767,000 | $698,000 | $678,000 | $703,000 |
| Stock-based compensation | $2.08M | $2.36M | $2.46M | $2.01M | $3.01M | $3.27M | $3.41M | $2.71M |
Free plan shows the latest 8 periods; Pro shows all 26 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.